Guideline on treating community-acquired pneumonia with Chinese patent medicines.
Pharmacol Res
; 196: 106919, 2023 Oct.
Article
en En
| MEDLINE
| ID: mdl-37722517
Community-acquired pneumonia (CAP) is one of the most common infectious diseases, and its morbidity and mortality increase with age. Resistance and mutations development make the use of anti-infective therapy challenging. Chinese patent medicines (CPMs) are often used to treat CAP in China and well tolerable. However, currently there are no evidence-based guideline for the treatment of CAP with CPMs, and the misuse of CPMs is common. Therefore, we established a guideline panel to develop this guideline. We identified six clinical questions through two rounds of survey, and we then systematically searched relevant evidence and performed meta-analyses, evidence summaries and GRADE decision tables to draft recommendations, which were then voted on by a consensus panel using the Delphi method. Finally, we developed ten recommendations based on evidence synthesis and expert consensus. For the treatment of severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Xuebijing injection, Shenfu injection, and Shenmai injection respectively. For the treatment of non-severe CAP in adults, we recommend Tanreqing injection, Reduning injection, Lianhua Qingwen capsule/granule, Qingfei Xiaoyan Pill and Shufeng Jiedu capsule respectively. CPMs have great potential to help in the fight against CAP worldwide, but more high-quality studies are still needed to strengthen the evidence.
Amygdalin (PubChem CID: 656516); Chinese patent medicines; Clinical practice guideline; Community-acquired pneumonia; Forsythoside A (PubChem CID: 5281773); GRADE; Ginsenoside Rg3 (PubChem CID: 9918693); Licochalcone A (PubChem CID: 5318998); Ligustilide (PubChem CID: 5319022); Luteolin (PubChem CID: 5280445); Quercetin (PubChem CID: 5280343); Resveratrol (PubChem CID: 445154); Saikosaponin A (PubChem CID: 167928); Skullcap (PubChem CID: 156595888)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Guideline
/
Prognostic_studies
/
Qualitative_research
Idioma:
En
Revista:
Pharmacol Res
Asunto de la revista:
FARMACOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Países Bajos